| NCT03910478 |
Dried Blood Spot Testing of CMV Detection in HCT Recipients |
https://ClinicalTrials.gov/show/NCT03910478 |
Recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2024-12-30 |
| NCT03382405 |
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults |
https://ClinicalTrials.gov/show/NCT03382405 |
Active, not recruiting |
ModernaTX, Inc. |
2020-07-31 |
| NCT03301415 |
Asymptomatic Congenital CMV Treatment |
https://ClinicalTrials.gov/show/NCT03301415 |
Recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2024-07-01 |
| NCT03266640 |
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) |
https://ClinicalTrials.gov/show/NCT03266640 |
Recruiting |
New York Medical College |
2020-12-31 |
| NCT03159364 |
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections |
https://ClinicalTrials.gov/show/NCT03159364 |
Recruiting |
Shenzhen Geno-Immune Medical Institute |
2020-07-31 |
| NCT03067155 |
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. |
https://ClinicalTrials.gov/show/NCT03067155 |
Recruiting |
University Hospital, Ghent |
2022-12-31 |
| NCT03004261 |
CMV-CTL for the Treatment of CMV Infection After HSCT |
https://ClinicalTrials.gov/show/NCT03004261 |
Recruiting |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2020-12-31 |
| NCT02985775 |
Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation |
https://ClinicalTrials.gov/show/NCT02985775 |
Completed |
Peking University People’s Hospital |
2018-03-31 |
| NCT02982902 |
T Cell Therapy of Opportunistic Cytomegalovirus Infection |
https://ClinicalTrials.gov/show/NCT02982902 |
Recruiting |
Case Comprehensive Cancer Center |
2020-12-31 |
| NCT02943057 |
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis |
https://ClinicalTrials.gov/show/NCT02943057 |
Recruiting |
Singapore National Eye Centre |
2021-12-31 |
| NCT02826798 |
Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults |
https://ClinicalTrials.gov/show/NCT02826798 |
Completed |
VBI Vaccines Inc. |
2016-09-15 |
| NCT02798692 |
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV |
https://ClinicalTrials.gov/show/NCT02798692 |
Completed |
Hookipa Biotech |
2017-05-31 |
| NCT02784756 |
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients |
https://ClinicalTrials.gov/show/NCT02784756 |
Recruiting |
University Health Network, Toronto |
2019-12-31 |
| NCT02683291 |
Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients |
https://ClinicalTrials.gov/show/NCT02683291 |
Completed |
Associação Médico EspÃrita de Botucatu |
2015-01-31 |
| NCT02680743 |
Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit |
https://ClinicalTrials.gov/show/NCT02680743 |
Completed |
University of Nebraska |
2018-05-31 |
| NCT02671318 |
Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence |
https://ClinicalTrials.gov/show/NCT02671318 |
Recruiting |
Hospital do Rim e Hipertensão |
2019-12-31 |
| NCT01646645 |
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01646645 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-06-30 |
| NCT02136797 |
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02136797 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-06-30 |
| NCT01251744 |
Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus |
https://ClinicalTrials.gov/show/NCT01251744 |
Completed |
GlaxoSmithKline |
2013-11-06 |
| NCT02550639 |
Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant |
https://ClinicalTrials.gov/show/NCT02550639 |
Completed |
Hospital Universitari de Bellvitge |
2018-09-30 |
| NCT02506933 |
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant |
https://ClinicalTrials.gov/show/NCT02506933 |
Active, not recruiting |
City of Hope Medical Center |
2018-10-31 |
| NCT02454699 |
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers |
https://ClinicalTrials.gov/show/NCT02454699 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2017-04-01 |
| NCT02396134 |
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02396134 |
Recruiting |
City of Hope Medical Center |
2020-05-31 |
| NCT02351102 |
Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy |
https://ClinicalTrials.gov/show/NCT02351102 |
Completed |
Rabin Medical Center |
2019-07-31 |
| NCT02328963 |
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A |
https://ClinicalTrials.gov/show/NCT02328963 |
Completed |
University Hospital, Bordeaux |
2018-10-10 |
| NCT02313857 |
Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) |
https://ClinicalTrials.gov/show/NCT02313857 |
Completed |
AlloVir |
2017-05-31 |
| NCT02210078 |
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection |
https://ClinicalTrials.gov/show/NCT02210078 |
Recruiting |
M.D. Anderson Cancer Center |
2020-02-28 |
| NCT02139423 |
Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening |
https://ClinicalTrials.gov/show/NCT02139423 |
Active, not recruiting |
Assistance Publique - Hôpitaux de Paris |
2018-03-31 |
| NCT02137772 |
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) |
https://ClinicalTrials.gov/show/NCT02137772 |
Completed |
Merck Sharp & Dohme Corp. |
2016-08-08 |
| NCT02134184 |
The Influence of Chronic CMV Infection on Influenza Vaccine Responses |
https://ClinicalTrials.gov/show/NCT02134184 |
Completed |
Stanford University |
2012-12-31 |
| NCT02103426 |
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients |
https://ClinicalTrials.gov/show/NCT02103426 |
Completed |
Astellas Pharma Inc |
2016-05-10 |
| NCT02084446 |
Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant |
https://ClinicalTrials.gov/show/NCT02084446 |
Completed |
Hospital Geral de Fortaleza |
2014-07-31 |
| NCT03354728 |
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03354728 |
Recruiting |
City of Hope Medical Center |
2021-05-11 |
| NCT02007356 |
A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® |
https://ClinicalTrials.gov/show/NCT02007356 |
Recruiting |
University Hospital, Basel, Switzerland |
2020-12-31 |
| NCT01986010 |
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) |
https://ClinicalTrials.gov/show/NCT01986010 |
Completed |
Merck Sharp & Dohme Corp. |
2016-04-19 |
| NCT01972035 |
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation |
https://ClinicalTrials.gov/show/NCT01972035 |
Active, not recruiting |
University of Minnesota |
2020-10-31 |
| NCT01941056 |
Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus |
https://ClinicalTrials.gov/show/NCT01941056 |
Completed |
City of Hope Medical Center |
2017-07-28 |
| NCT01923636 |
Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero |
https://ClinicalTrials.gov/show/NCT01923636 |
Active, not recruiting |
Assistance Publique - Hôpitaux de Paris |
2020-06-30 |
| NCT01819519 |
Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus |
https://ClinicalTrials.gov/show/NCT01819519 |
Completed |
Women and Infants Hospital of Rhode Island |
2015-03-31 |
| NCT01753167 |
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients |
https://ClinicalTrials.gov/show/NCT01753167 |
Completed |
Genentech, Inc. |
2014-10-15 |
| NCT01691820 |
A Study in Adolescent Females to Explore Cytomegalovirus Infection |
https://ClinicalTrials.gov/show/NCT01691820 |
Completed |
GlaxoSmithKline |
2017-04-08 |
| NCT01663740 |
A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls |
https://ClinicalTrials.gov/show/NCT01663740 |
Completed |
Hoffmann-La Roche |
2015-09-29 |
| NCT01649869 |
Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss |
https://ClinicalTrials.gov/show/NCT01649869 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2019-12-24 |
| NCT01611974 |
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients |
https://ClinicalTrials.gov/show/NCT01611974 |
Completed |
Shire |
2014-12-05 |
| NCT01594437 |
Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody |
https://ClinicalTrials.gov/show/NCT01594437 |
Completed |
Theraclone Sciences, Inc. |
2012-12-31 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01552369 |
CMV Antiviral Prevention Strategies in D+R-Liver Transplants (“CAPSIL”) |
https://ClinicalTrials.gov/show/NCT01552369 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2018-06-22 |
| NCT01535885 |
Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV |
https://ClinicalTrials.gov/show/NCT01535885 |
Completed |
Medical College of Wisconsin |
2019-10-31 |
| NCT01509404 |
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection |
https://ClinicalTrials.gov/show/NCT01509404 |
Completed |
Medical University of South Carolina |
2014-12-31 |
| NCT01376804 |
A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients |
https://ClinicalTrials.gov/show/NCT01376804 |
Completed |
Hoffmann-La Roche |
2013-05-31 |
| NCT01376778 |
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) |
https://ClinicalTrials.gov/show/NCT01376778 |
Active, not recruiting |
The George Washington University Biostatistics Center |
2018-12-31 |
| NCT01357915 |
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals’ Candidate Cytomegalovirus (CMV) Vaccine |
https://ClinicalTrials.gov/show/NCT01357915 |
Completed |
GlaxoSmithKline |
2012-09-13 |
| NCT01354301 |
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate |
https://ClinicalTrials.gov/show/NCT01354301 |
Completed |
Hospital do Rim e Hipertensão |
2014-04-30 |
| NCT04364178 |
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV |
https://ClinicalTrials.gov/show/NCT04364178 |
Recruiting |
University of Pittsburgh |
2025-04-01 |
| NCT04320303 |
CMV Infection and Immune Intervention After Transplantation |
https://ClinicalTrials.gov/show/NCT04320303 |
Recruiting |
Peking University People’s Hospital |
2020-12-31 |
| NCT01325636 |
Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus |
https://ClinicalTrials.gov/show/NCT01325636 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2014-01-31 |
| NCT04232280 |
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults |
https://ClinicalTrials.gov/show/NCT04232280 |
Active, not recruiting |
ModernaTX, Inc. |
2021-08-31 |
| NCT04225923 |
A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection |
https://ClinicalTrials.gov/show/NCT04225923 |
Recruiting |
Nobelpharma |
2022-01-31 |
| NCT04153279 |
CMV-TCR-T Cells for CM Virus Infection After HSCT |
https://ClinicalTrials.gov/show/NCT04153279 |
Recruiting |
Hebei Yanda Ludaopei Hospital |
2021-10-01 |
| NCT04129398 |
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) |
https://ClinicalTrials.gov/show/NCT04129398 |
Recruiting |
Merck Sharp & Dohme Corp. |
2022-04-15 |
| NCT04067869 |
Cytomegalovirus Infection in Patients With HIV-1 Infection |
https://ClinicalTrials.gov/show/NCT04067869 |
Completed |
University Hospital, Bordeaux |
2010-12-13 |
| NCT04030676 |
QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04030676 |
Recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2021-01-31 |
| NCT04017962 |
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection |
https://ClinicalTrials.gov/show/NCT04017962 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-07-31 |
| NCT03973359 |
Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy |
https://ClinicalTrials.gov/show/NCT03973359 |
Recruiting |
Foundation IRCCS San Matteo Hospital |
2020-07-31 |
| NCT03950414 |
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Kidney Transplant Recipients |
https://ClinicalTrials.gov/show/NCT03950414 |
Recruiting |
University of Wisconsin, Madison |
2023-08-31 |
| NCT03840174 |
Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) |
https://ClinicalTrials.gov/show/NCT03840174 |
Completed |
Merck Sharp & Dohme Corp. |
2019-11-07 |
| NCT03806764 |
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient |
https://ClinicalTrials.gov/show/NCT03806764 |
Enrolling by invitation |
Melbourne Health |
2020-03-31 |
| NCT03798301 |
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells |
https://ClinicalTrials.gov/show/NCT03798301 |
Recruiting |
University of Wisconsin, Madison |
2023-09-01 |
| NCT03728426 |
Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection |
https://ClinicalTrials.gov/show/NCT03728426 |
Recruiting |
Dana-Farber Cancer Institute |
2020-12-31 |
| NCT03699254 |
Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients. |
https://ClinicalTrials.gov/show/NCT03699254 |
Recruiting |
Maimónides Biomedical Research Institute of Córdoba |
2023-04-30 |
| NCT03631316 |
Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir |
https://ClinicalTrials.gov/show/NCT03631316 |
Completed |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2018-10-30 |
| NCT03511274 |
Reducing Acquisition of CMV Through Antenatal Education |
https://ClinicalTrials.gov/show/NCT03511274 |
Recruiting |
St George’s, University of London |
2020-07-31 |
| NCT03486834 |
Safety, Tolerability, and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002) |
https://ClinicalTrials.gov/show/NCT03486834 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2021-05-14 |
| NCT03475212 |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03475212 |
Recruiting |
Children’s Hospital Los Angeles |
2022-02-28 |
| NCT01220895 |
Alternate Donor Study of Pre-Emptive Cellular Therapy |
https://ClinicalTrials.gov/show/NCT01220895 |
Completed |
Cell Medica Ltd |
2013-12-31 |
| NCT01178905 |
Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants |
https://ClinicalTrials.gov/show/NCT01178905 |
Completed |
University Hospital Tuebingen |
2012-10-31 |
| NCT01165580 |
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age |
https://ClinicalTrials.gov/show/NCT01165580 |
Completed |
Hoffmann-La Roche |
2013-09-30 |
| NCT01077908 |
Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study |
https://ClinicalTrials.gov/show/NCT01077908 |
Completed |
Cell Medica Ltd |
2014-09-30 |
| NCT01070797 |
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) |
https://ClinicalTrials.gov/show/NCT01070797 |
Completed |
Baylor College of Medicine |
2013-05-31 |
| NCT00947141 |
Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) |
https://ClinicalTrials.gov/show/NCT00947141 |
Completed |
University College, London |
2011-12-31 |
| NCT00942305 |
Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control Cytomegalovirus (CMV) Infection in R+ Hematopoietic Stem Cell Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00942305 |
Completed |
Chimerix |
2012-01-31 |
| NCT00881517 |
Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection |
https://ClinicalTrials.gov/show/NCT00881517 |
Completed |
IRCCS Policlinico S. Matteo |
2011-10-31 |
| NCT00880789 |
Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus |
https://ClinicalTrials.gov/show/NCT00880789 |
Completed |
Baylor College of Medicine |
2013-08-31 |
| NCT03930615 |
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) |
https://ClinicalTrials.gov/show/NCT03930615 |
Recruiting |
Merck Sharp & Dohme Corp. |
2021-08-08 |
| NCT00730769 |
Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients |
https://ClinicalTrials.gov/show/NCT00730769 |
Completed |
Hospital Universitari de Bellvitge |
2007-07-31 |
| NCT00716911 |
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00716911 |
Completed |
City of Hope Medical Center |
2007-07-31 |
| NCT00699868 |
Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients |
https://ClinicalTrials.gov/show/NCT00699868 |
Completed |
Assistance Publique Hopitaux De Marseille |
2011-01-31 |
| NCT00674648 |
Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants |
https://ClinicalTrials.gov/show/NCT00674648 |
Completed |
Memorial Sloan Kettering Cancer Center |
2014-03-31 |
| NCT00673868 |
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants |
https://ClinicalTrials.gov/show/NCT00673868 |
Completed |
Milton S. Hershey Medical Center |
2008-08-06 |
| NCT00566072 |
The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial |
https://ClinicalTrials.gov/show/NCT00566072 |
Completed |
University Hospital, Ghent |
NA |
| NCT00497796 |
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00497796 |
Completed |
Shire |
2009-05-31 |
| NCT00466817 |
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections |
https://ClinicalTrials.gov/show/NCT00466817 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2011-12-31 |
| NCT00461695 |
Influence of Persistent CMV-infection on Immune Senescence |
https://ClinicalTrials.gov/show/NCT00461695 |
Completed |
University of Zurich |
2008-08-31 |
| NCT00439803 |
A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV) |
https://ClinicalTrials.gov/show/NCT00439803 |
Completed |
AlphaVax, Inc. |
2008-07-31 |
| NCT00435396 |
Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects |
https://ClinicalTrials.gov/show/NCT00435396 |
Completed |
GlaxoSmithKline |
2008-08-27 |
| NCT00431353 |
VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00431353 |
Completed |
Hoffmann-La Roche |
2008-08-31 |
| NCT00411645 |
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00411645 |
Completed |
Shire |
2008-11-30 |
| NCT00386412 |
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant |
https://ClinicalTrials.gov/show/NCT00386412 |
Completed |
PETHEMA Foundation |
2009-09-30 |
| NCT00377741 |
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis. |
https://ClinicalTrials.gov/show/NCT00377741 |
Completed |
Hoffmann-La Roche |
2006-06-30 |
| NCT00374686 |
Study of Prophylactic Vs Preemptive Valganciclovir |
https://ClinicalTrials.gov/show/NCT00374686 |
Completed |
Washington University School of Medicine |
NA |
| NCT00373412 |
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge |
https://ClinicalTrials.gov/show/NCT00373412 |
Completed |
University of California, San Francisco |
2008-02-29 |
| NCT00373165 |
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients |
https://ClinicalTrials.gov/show/NCT00373165 |
Completed |
Lower Saxony Center for Nephrology |
NA |
| NCT00372229 |
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation |
https://ClinicalTrials.gov/show/NCT00372229 |
Completed |
Hoffmann-La Roche |
2015-10-31 |
| NCT00370006 |
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM |
https://ClinicalTrials.gov/show/NCT00370006 |
Completed |
University of California, San Francisco |
NA |
| NCT00353977 |
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors |
https://ClinicalTrials.gov/show/NCT00353977 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-03-31 |
| NCT00294515 |
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients |
https://ClinicalTrials.gov/show/NCT00294515 |
Completed |
Hoffmann-La Roche |
2008-08-31 |
| NCT00284687 |
Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00284687 |
Completed |
Hadassah Medical Organization |
2010-03-31 |
| NCT00264290 |
Valganciclovir to Reduce T Cell Activation in HIV Infection |
https://ClinicalTrials.gov/show/NCT00264290 |
Completed |
University of California, San Francisco |
2008-10-31 |
| NCT00227370 |
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation |
https://ClinicalTrials.gov/show/NCT00227370 |
Completed |
Duke University |
2008-04-30 |
| NCT00223925 |
Maribavir for Prevention of CMV After Stem Cell Transplants |
https://ClinicalTrials.gov/show/NCT00223925 |
Completed |
Shire |
2006-04-30 |
| NCT00133497 |
gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females |
https://ClinicalTrials.gov/show/NCT00133497 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2013-06-30 |
| NCT00125502 |
Recombinant CMV gB Vaccine in Postpartum Women |
https://ClinicalTrials.gov/show/NCT00125502 |
Completed |
University of Alabama at Birmingham |
2007-06-30 |
| NCT00090766 |
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00090766 |
Completed |
Hoffmann-La Roche |
2005-05-31 |
| NCT00078533 |
Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078533 |
Completed |
Baylor College of Medicine |
2010-07-31 |
| NCT00016068 |
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00016068 |
Completed |
Fred Hutchinson Cancer Research Center |
NA |
| NCT00001890 |
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections |
https://ClinicalTrials.gov/show/NCT00001890 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00031434 |
Valganciclovir in Congenital CMV Infants |
https://ClinicalTrials.gov/show/NCT00031434 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2007-07-31 |
| NCT00006145 |
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV |
https://ClinicalTrials.gov/show/NCT00006145 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00002373 |
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients |
https://ClinicalTrials.gov/show/NCT00002373 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002352 |
A Study of Lobucavir in Patients With AIDS |
https://ClinicalTrials.gov/show/NCT00002352 |
Completed |
Bristol-Myers Squibb |
NA |
| NCT00002268 |
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria |
https://ClinicalTrials.gov/show/NCT00002268 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002251 |
A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir |
https://ClinicalTrials.gov/show/NCT00002251 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002146 |
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study |
https://ClinicalTrials.gov/show/NCT00002146 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002096 |
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine |
https://ClinicalTrials.gov/show/NCT00002096 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002095 |
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus |
https://ClinicalTrials.gov/show/NCT00002095 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002025 |
Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient |
https://ClinicalTrials.gov/show/NCT00002025 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00002024 |
Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections |
https://ClinicalTrials.gov/show/NCT00002024 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00001100 |
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. |
https://ClinicalTrials.gov/show/NCT00001100 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00001082 |
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients |
https://ClinicalTrials.gov/show/NCT00001082 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
1999-01-31 |
| NCT00001038 |
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients |
https://ClinicalTrials.gov/show/NCT00001038 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
1996-05-31 |
| NCT00000995 |
A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection |
https://ClinicalTrials.gov/show/NCT00000995 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00000981 |
The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS |
https://ClinicalTrials.gov/show/NCT00000981 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00000805 |
A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease |
https://ClinicalTrials.gov/show/NCT00000805 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00004642 |
Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease |
https://ClinicalTrials.gov/show/NCT00004642 |
Completed |
Office of Rare Diseases (ORD) |
NA |
| NCT00000593 |
Viral Activation Transfusion Study (VATS) |
https://ClinicalTrials.gov/show/NCT00000593 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
NA |
| NCT00000584 |
Transfusion-Transmitted Cytomegalovirus Prevention in Neonates |
https://ClinicalTrials.gov/show/NCT00000584 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
NA |
| NCT00004278 |
Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection |
https://ClinicalTrials.gov/show/NCT00004278 |
Completed |
Office of Rare Diseases (ORD) |
NA |